MGRN1 is a RING-finger E3 ubiquitin ligase that mediates protein monoubiquitination and regulates multiple cellular pathways critical for normal physiology and cancer biology. Functionally, MGRN1 catalyzes monoubiquitination of TSG101 in conjunction with UBE2D1 1, regulates endosome-to-lysosome trafficking 1, and negatively modulates melanocortin receptor signaling by competing with GNAS binding and inhibiting cAMP production 2. In melanoma, MGRN1 functions as a phenotypic determinant and prognostic biomarker. MGRN1 depletion induces cell differentiation, increases E-cadherin expression, enhances intercellular adhesion, and reduces CDC42 activation 3. Loss of MGRN1 increases genomic instability and DNA breaks in human melanoma cells 4. High MGRN1 expression correlates inversely with melanoma patient survival and appears elevated in melanomas compared to normal skin 4. A four-gene signature combining MGRN1 with melanocyte-specific genes (MLANA, PMEL, TYRP1) identifies low-medium TNM stage patients with adverse outcomes 5. Beyond melanoma, MGRN1 loss causes spongiform neurodegeneration, congenital heart defects, and mitochondrial dysfunction 6. In hepatocellular carcinoma, MGRN1 promotes TBX19 degradation, enhancing sorafenib sensitivity and immune responses 7. MGRN1 loss in lung adenocarcinoma impairs cuproptosis protection through LIPT1 stabilization and glycolysis reprogramming 8.